EscharEx
Debridement of Venous Leg Ulcers (VLU)
Key Facts
About MediWound
MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.
View full company profileAbout MediWound
MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.
View full company profileAbout MediWound
MediWound is an Israeli biotech company with a mission to deliver innovative, cost-effective enzymatic solutions for severe burn care and hard-to-heal wounds. Its key achievement is the global regulatory approval and commercialization of NexoBrid, an orphan biologic for burn eschar removal, including recent FDA approval in December 2023. The company's strategy leverages a fully integrated, vertically operational model—spanning R&D, cGMP manufacturing, and targeted commercialization—to advance its core bromelain-based platform into large chronic wound markets, with EscharEx currently in Phase 3 trials.
View full company profile